NCT01029132View on ClinicalTrials.gov

Characteristics of Treatment Responders to Galantamine

NACompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Dementia
Interventions
DRUG

galantamine

8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

All Listed Sponsors
collaborator

Janssen Korea, Ltd., Korea

INDUSTRY

lead

Samsung Medical Center

OTHER

NCT01029132 - Characteristics of Treatment Responders to Galantamine | Biotech Hunter | Biotech Hunter